Essity integrates BSN medical India into its fold

Mumbai: Leading global health and hygiene company, Essity, announced the final step in integrating BSN medical India into the Essity organization. Following the global acquisition of BSN medical in April 2017, the business in India continues its journey as Essity India, with a sharp focus on the medical and healthcare solutions market.

Emerging markets, including India, accounted for 35% of Essity’s global net sales in 2018. Essity India, aims to further strengthen its market position across three key portfolios: orthopedics, wound care and compression therapy.

  • Orthopedics: Solutions for fracture management, physiotherapy, orthopedic soft goods and braces
  • Woundcare: Solutions for acute and advanced wound care like surgical tapes, retention bandages, surgical/post-operation dressings, adhesive bandages/plasters
  • Compression therapy: Phlebology and lymphology solutions like compression bandages, compression stockings, pneumatic compression pumps, etc.

The three portfolios include heritage brands such as Delta-Cast, Actimove, Leukoplast, Cutimed and JOBST.

Speaking on this final step in the integration and launch of Essity India, Mr. Neeraj Raghuvanshi, Managing Director, Essity India said, “We are pleased to bring the global heritage of Essity to India. Our goal for the next two years is to strengthen the existing business and attain strong growth for the company. With our integrated therapy solutions, backed by cutting edge technology, we hope to positively contribute to the healthcare needs of Indian patients.”

In India, Essity will also work towards its global commitment to six key United Nations Sustainable Development Goals (UN SDGs), namely – Good health and well-being, Gender equality, Clean water and sanitation, Responsible consumption and production, Climate action and Life on land.

Mr. Carl-Magnus Stensson, Vice President Sales & Marketing, Asia Pacific – Health and Medical Solutions, Essity said, “Through our business operations, domain expertise and partnerships with others who share the same challenges and opportunities, we continuously work towards creating synergies that contribute to the achievement of the UN SDGs.”

“Sustainability is at the core of everything we do, and we hope to continue developing solutions through a sustainable approach. In India, our state-of-the-art manufacturing facilities in Goa, cater to the supply requirements of close to 60 countries, spanning across Asia-Pacific, Latin America and Africa. With the current expansion of our global legacy brands such as Leukoplast, Gypsona, Leukocrepe and the growing medical and healthcare needs of India, the country will continue to be a key regional business hub for Essity,” Mr.Stensson added.

Recently, Essity was recognized in The Sustainability Yearbook 2019 for the Household Product industry and received the Gold Class and Industry Mover distinction for excellent sustainability performance, by RobecoSAM’s ranking.

RobecoSAM is an investment specialist focused exclusively on Sustainability Investing and annually assesses the world’s largest companies for the Dow Jones Sustainability Index (DJSI), one of the world’s most prestigious sustainability indices.

The company’s India headquarters are located in Mumbai with an employee base of more than 200 people.

Related Posts

Pain is passé in Blood Test, thanks to Metropolis’ Human Touch

New Delhi: Blood drawing for test has really reached proverbial ant bite, thanks to introduction of innovative blood collection technology by Metropolis healthcare, India’s second largest pathology laboratory chain. First…

60 Countries witnessed AMTZ, Seed of Global Hub of Medical Devices

Vishakhapatnam: It could be the beginning of the end of dependence of India on imports of medical devices. Import lobby must have watched this gathering of 60 countries to witness…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

India-Latin America trade and collaboration prospects discussed at Kerala University conference

India-Latin America trade and collaboration prospects discussed at Kerala University conference

Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt

Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt